It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The circadian clock, a fundamental biological regulator, governs essential cellular processes in health and disease. Circadian-based therapeutic strategies are increasingly gaining recognition as promising avenues. Aligning drug administration with the circadian rhythm can enhance treatment efficacy and minimize side effects. Yet, uncovering the optimal treatment timings remains challenging, limiting their widespread adoption. In this work, we introduce a high-throughput approach integrating live-imaging and data analysis techniques to deep-phenotype cancer cell models, evaluating their circadian rhythms, growth, and drug responses. We devise a streamlined process for profiling drug sensitivities across different times of the day, identifying optimal treatment windows and responsive cell types and drug combinations. Finally, we implement multiple computational tools to uncover cellular and genetic factors shaping time-of-day drug sensitivity. Our versatile approach is adaptable to various biological models, facilitating its broad application and relevance. Ultimately, this research leverages circadian rhythms to optimize anti-cancer drug treatments, promising improved outcomes and transformative treatment strategies.
The circadian rhythm has been linked to cancer cell sensitivity to therapy but tools to understand this further are limited. Here, by combining live-cell imaging and computational tools, the authors develop a high-throughput deep-phenotyping approach to evaluate circadian rhythms and use it to determine time-of-day drug sensitivity in cancer cell lines.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; De Landtsheer, Sébastien 3
; Finger, Anna-Marie 4
; Müller-Marquardt, Francesca 5 ; Schulte, Johannes H. 6
; Sauter, Thomas 3
; Keilholz, Ulrich 7 ; Herzel, Hanspeter 8 ; Kramer, Achim 9
; Granada, Adrián E. 7
1 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Humboldt-Universität zu Berlin, Faculty of Life Sciences, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639)
2 Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639)
3 University of Luxembourg, Department of Life Sciences and Medicine, Esch-sur-Alzette, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843)
4 Charité – Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); San Francisco, Department of Anatomy, University of California, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); University of Montpellier, Institute of Research for Development, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
6 Charité – Universitätsmedizin Berlin, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Universitätsklinikum Tübingen, Clinic for Pediatrics and Adolescent Medicine, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249)
7 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); German Cancer Consortium (DKTK), Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0004 7865 6683)
8 Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639); Charité – Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
9 Charité – Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)




